$MEIP
MEI Pharma, Inc.

2017 Q2 Form 10-K Financial Statement

#000119312518263586 Filed on August 30, 2018

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q4
Revenue $449.0K $4.505M $17.20M
YoY Change
Cost Of Revenue $990.0K $1.147M $1.771M
YoY Change
Gross Profit -$540.0K $3.358M $15.43M
YoY Change
Gross Profit Margin -120.27% 74.54% 89.7%
Selling, General & Admin $1.830M $2.150M $1.970M
YoY Change -0.54% 8.04% 1.03%
% of Gross Profit 64.03% 12.77%
Research & Development $2.070M $1.876M $1.642M
YoY Change -48.12% -45.15% -48.4%
% of Gross Profit 55.87% 10.64%
Depreciation & Amortization $50.00K $10.00K $20.00K
YoY Change 400.0% -50.0% 100.0%
% of Gross Profit 0.3% 0.13%
Operating Expenses $3.900M $1.876M $1.642M
YoY Change -32.99% -65.32% -67.97%
Operating Profit -$4.440M -$670.0K $11.82M
YoY Change -87.62% -330.47%
Interest Expense $100.0K $70.00K $70.00K
YoY Change 100.0% 75.0% 133.33%
% of Operating Profit 0.59%
Other Income/Expense, Net
YoY Change
Pretax Income -$4.340M -$600.0K $11.89M
YoY Change -24.78% -88.83% -333.14%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$4.343M -$602.0K $11.89M
YoY Change -24.73% -88.79% -332.99%
Net Earnings / Revenue -967.26% -13.36% 69.1%
Basic Earnings Per Share -$0.12 -$0.02 $0.32
Diluted Earnings Per Share -$0.12 -$0.02 $0.32
COMMON SHARES
Basic Shares Outstanding 36.77M shares 37.17M shares 37.17M shares
Diluted Shares Outstanding 37.17M shares 37.22M shares

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $53.60M $56.80M $55.20M
YoY Change 16.78% 14.98% 2.6%
Cash & Equivalents $8.458M $11.64M $15.05M
Short-Term Investments $45.10M $45.10M $40.10M
Other Short-Term Assets $1.800M $2.800M $2.700M
YoY Change 125.0% 154.55% 237.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $55.32M $59.52M $57.82M
YoY Change 18.34% 17.84% 5.95%
LONG-TERM ASSETS
Property, Plant & Equipment $50.00K $35.00K $40.00K
YoY Change 2.04% -33.96% -28.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $381.0K $375.0K $388.0K
YoY Change -8.19% -12.18% -11.62%
TOTAL ASSETS
Total Short-Term Assets $55.32M $59.52M $57.82M
Total Long-Term Assets $381.0K $375.0K $388.0K
Total Assets $55.70M $59.89M $58.21M
YoY Change 18.11% 17.59% 5.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $585.0K $242.0K $382.0K
YoY Change -45.78% -48.07% -14.73%
Accrued Expenses $3.285M $3.711M $2.938M
YoY Change -25.9% 4.27% 0.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.866M $4.989M $3.320M
YoY Change -11.72% 23.95% -1.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.866M $4.989M $3.320M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $4.866M $5.000M $3.300M
YoY Change -11.72% 25.0% -2.94%
SHAREHOLDERS EQUITY
Retained Earnings -$174.3M -$170.0M -$169.4M
YoY Change -1.51% -0.73% 2.13%
Common Stock $225.2M $224.9M $224.3M
YoY Change 2.98% 3.1% 3.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.84M $54.90M $54.89M
YoY Change
Total Liabilities & Shareholders Equity $55.70M $59.89M $58.21M
YoY Change 18.11% 17.59% 5.81%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q4
OPERATING ACTIVITIES
Net Income -$4.343M -$602.0K $11.89M
YoY Change -24.73% -88.79% -332.99%
Depreciation, Depletion And Amortization $50.00K $10.00K $20.00K
YoY Change 400.0% -50.0% 100.0%
Cash From Operating Activities -$3.140M $1.600M -$3.740M
YoY Change -10.03% -136.53% -11.58%
INVESTING ACTIVITIES
Capital Expenditures -$50.00K $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $10.00K -$5.020M $5.010M
YoY Change -66.67% -200.2% 24950.0%
Cash From Investing Activities -$40.00K -$5.010M $5.000M
YoY Change -233.33% -200.2% 24900.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -3.140M 1.600M -3.740M
Cash From Investing Activities -40.00K -5.010M 5.000M
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -3.180M -3.410M 1.260M
YoY Change -8.09% -650.0% -129.93%
FREE CASH FLOW
Cash From Operating Activities -$3.140M $1.600M -$3.740M
Capital Expenditures -$50.00K $0.00 $0.00
Free Cash Flow -$3.090M $1.600M -$3.740M
YoY Change -11.46% -136.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 us-gaap Fair Value Assumptions Exercise Price
FairValueAssumptionsExercisePrice
2.22
CY2018Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
36600000
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
71086404 shares
CY2017Q4 dei Entity Public Float
EntityPublicFloat
77700000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
59791000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18722000
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
41652000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10837000
CY2017Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
45000
CY2017Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
267000
CY2017Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
138000
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36772000 shares
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2019593 shares
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.57
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36772000 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4259083 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.21
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-174331000
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q2 us-gaap Liabilities
Liabilities
4866000
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55704000
CY2017Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1546000
CY2017Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
996000
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
585000
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
50838000
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
225169000
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4866000
CY2017Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
44535000
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3285000
CY2017Q2 us-gaap Assets Current
AssetsCurrent
55323000
CY2017Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
325000
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8458000
CY2017Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7886000
CY2017Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
630000
CY2017Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
53565000
CY2017Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5621000
CY2017Q2 us-gaap Short Term Investments
ShortTermInvestments
45107000
CY2017Q2 us-gaap Assets
Assets
55704000
CY2017Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
44535000
CY2017Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
331000
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1758000
CY2017Q2 meip Deferred Tax Assets Capital Lease Obligations
DeferredTaxAssetsCapitalLeaseObligations
413000
CY2017Q2 meip Deferred Tax Assets Property Plant And Equipment And Intangible Assets
DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets
29660000
CY2017Q2 meip Accrued Preclinical And Clinical Costs
AccruedPreclinicalAndClinicalCosts
1334000
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
113100000 shares
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70406000 shares
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
3232930 shares
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.15
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70406000 shares
CY2018Q2 us-gaap Fair Value Assumptions Exercise Price
FairValueAssumptionsExercisePrice
2.81
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3048685 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.40
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6281615 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.08
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-214399000
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q2 us-gaap Liabilities
Liabilities
54198000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
104657000
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1766000
CY2018Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
788000
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3643000
CY2018Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
46313000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
50459000
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
264858000
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
49000
CY2018Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
251000
CY2018Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q2 us-gaap Contractual Obligation
ContractualObligation
1100000
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
203000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7885000
CY2018Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
29621000
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3454000
CY2018Q2 us-gaap Assets Current
AssetsCurrent
104329000
CY2018Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
17800000
CY2018Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
35000
CY2018Q2 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
11000
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32000
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4846546
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13309000
CY2018Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8893000
CY2018Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
367000
CY2018Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
102743000
CY2018Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
36400000
CY2018Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2354000
CY2018Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4300000
CY2018Q2 us-gaap Short Term Investments
ShortTermInvestments
89434000
CY2018Q2 us-gaap Assets
Assets
104657000
CY2018Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
29621000
CY2018Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
296000
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1586000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8942979
CY2018Q2 meip Shelf Registration Statement Value
ShelfRegistrationStatementValue
150000000
CY2018Q2 meip Deferred Tax Assets Capital Lease Obligations
DeferredTaxAssetsCapitalLeaseObligations
171000
CY2018Q2 meip Deferred Tax Assets Property Plant And Equipment And Intangible Assets
DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets
17790000
CY2018Q2 meip Accrued Preclinical And Clinical Costs
AccruedPreclinicalAndClinicalCosts
1234000
CY2018Q2 meip Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
75200000
CY2018Q2 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000 pure
CY2018Q2 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.756 pure
CY2018Q2 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.029 pure
CY2018Q2 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2018Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
70200000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7331 shares
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-10.36 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.00 pure
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36938000 shares
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36813000 shares
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.06 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.013 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.15
CY2017 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
36435000 shares
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.08 pure
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-27655000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4212000
CY2017 meip Effective Income Tax Rate Reconciliation Revaluation Of Deferred Taxes
EffectiveIncomeTaxRateReconciliationRevaluationOfDeferredTaxes
0.00 pure
CY2017 meip Effective Income Tax Rate Reconciliation Nondeductible Expense Stock Issuance Cost Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStockIssuanceCostPercent
0.00 pure
CY2017 meip Income Tax Reconciliation Capital Loss Expirations
IncomeTaxReconciliationCapitalLossExpirations
26382000
CY2017 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
125000 shares
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3486000
CY2017 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.074 pure
CY2017 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
378000 shares
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2400000
CY2017 us-gaap Revenues
Revenues
23249000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
51000
CY2017 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
2369000
CY2017 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
60123000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
2384000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
2670000
CY2017 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
287000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2304000
CY2017 us-gaap Profit Loss
ProfitLoss
2670000
CY2017 us-gaap Licenses Revenue
LicensesRevenue
20880000
CY2017 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-1000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4212000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
927000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2670000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
2670000
CY2017 us-gaap Depreciation
Depreciation
50000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
85000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2017 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-494000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
2304000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
908000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
996000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10077000
CY2017 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
4212000
CY2017 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
50097000
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
20865000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8628000
CY2017 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
208000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1148000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7237000
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
35000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2379000
CY2017 us-gaap Cost Of Services
CostOfServices
5000000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
158000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
329000
CY2018 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
2400000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-172000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-40068000
CY2017 meip Effective Income Tax Rate Reconciliation Capital Loss Expirations
EffectiveIncomeTaxRateReconciliationCapitalLossExpirations
9.88 pure
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9474 shares
CY2018 us-gaap Common Stock Voting Rights
CommonStockVotingRights
One vote per share
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Type
DocumentType
10-K
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.97
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.275 pure
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.37 pure
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.02 pure
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001262104
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P14Y
CY2018 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-9705000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3217000
CY2018 us-gaap Profit Loss
ProfitLoss
-40068000
CY2018 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-1000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
238249 shares
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.71
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
6.76
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018 dei Trading Symbol
TradingSymbol
MEIP
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41431000 shares
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41431000 shares
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.13 pure
CY2018 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000 pure
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.84
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.44
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.14
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.023 pure
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
318615 shares
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.40
CY2018 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
41064000 shares
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.97
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01 pure
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.773 pure
CY2018 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.027 pure
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21302000
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2018 meip Agreement Termination Notice Period
AgreementTerminationNoticePeriod
P90D
CY2018 meip Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2020-05
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2772333 shares
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
1321369 shares
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
192937 shares
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates.</p> </div>
CY2018 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M24D
CY2018 dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P4Y9M18D
CY2018 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
114233000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-28586000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-40068000
CY2018 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
591000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.937 pure
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
237627 shares
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
1.89
CY2018 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
367000 shares
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2400000
CY2018 us-gaap Revenues
Revenues
1622000
CY2018 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
1622000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70480000
CY2018 meip Effective Income Tax Rate Reconciliation Revaluation Of Deferred Taxes
EffectiveIncomeTaxRateReconciliationRevaluationOfDeferredTaxes
-0.40 pure
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
329000
CY2018 us-gaap Cost Of Services
CostOfServices
3383000
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
5370000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-14914000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-40068000
CY2018 us-gaap Depreciation
Depreciation
18000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
53000
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
15870000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2018 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
3058000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
3217000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-11019000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
837000
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-208000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-44327000
CY2018 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
70151000
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
69906000
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
30208000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9787000
CY2018 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
537000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
402000
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
46000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17038000
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
35000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4851000
CY2018 meip Lease Arrangement Rent Area
LeaseArrangementRentArea
13700 sqft
CY2018 meip Effective Income Tax Rate Reconciliation Nondeductible Expense Stock Issuance Cost Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStockIssuanceCostPercent
-0.08 pure
CY2018 meip Lease Commencement Month And Year
LeaseCommencementMonthAndYear
2017-06
CY2018 meip Percentage Of Purchases From Major Suppliers
PercentageOfPurchasesFromMajorSuppliers
1.00 pure
CY2018 meip Effective Income Tax Rate Reconciliation Capital Loss Expirations
EffectiveIncomeTaxRateReconciliationCapitalLossExpirations
0.00 pure
CY2018 meip Number Of Clinical Stage Candidates
NumberOfClinicalStageCandidates
4 ClinicalTrials
CY2018 meip Number Of Candidate In An Ongoing Global Registration Trial
NumberOfCandidateInAnOngoingGlobalRegistrationTrial
1 ClinicalTrials
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17857000
CY2016 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2016 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
244000 shares
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3100000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.167 pure
CY2016 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
55238000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-21004000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-20862000
CY2016 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
143000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2723000
CY2016 us-gaap Profit Loss
ProfitLoss
-20862000
CY2018 meip Warrant Finance Cost
WarrantFinanceCost
2367000
CY2018 meip Income Tax Rate Reconciliation Nondeductible Expense Stock Issuance Cost
IncomeTaxRateReconciliationNondeductibleExpenseStockIssuanceCost
3320
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6628 shares
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.38 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.00 pure
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34400000 shares
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34400000 shares
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.06 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.35
CY2016 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
34156000 shares
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.02 pure
CY2016 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-1000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
329000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-20862000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-20862000
CY2016 us-gaap Depreciation
Depreciation
23000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
58000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2016 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
216000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
2723000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7093000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9972000
CY2016 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
65214000
CY2016 us-gaap Costs And Expenses
CostsAndExpenses
21004000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7601000
CY2016 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
356000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
337000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13403000
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
35000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7885000
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1215000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7953000
CY2016 meip Effective Income Tax Rate Reconciliation Revaluation Of Deferred Taxes
EffectiveIncomeTaxRateReconciliationRevaluationOfDeferredTaxes
0.00 pure
CY2016 meip Effective Income Tax Rate Reconciliation Nondeductible Expense Stock Issuance Cost Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStockIssuanceCostPercent
0.00 pure
CY2016 meip Effective Income Tax Rate Reconciliation Capital Loss Expirations
EffectiveIncomeTaxRateReconciliationCapitalLossExpirations
0.00 pure
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2017Q1 us-gaap Revenues
Revenues
4505000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-602000
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2018Q1 us-gaap Revenues
Revenues
433000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-5948000
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2017Q2 us-gaap Revenues
Revenues
449000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-4343000
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2018Q2 us-gaap Revenues
Revenues
548000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-19253000
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2016Q3 us-gaap Revenues
Revenues
1096000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-4270000
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.32
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
CY2016Q4 us-gaap Revenues
Revenues
17199000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
11885000
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2017Q3 us-gaap Revenues
Revenues
283000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-8788000
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2017Q4 us-gaap Revenues
Revenues
358000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-6079000

Files In Submission

Name View Source Status
0001193125-18-263586-index-headers.html Edgar Link pending
0001193125-18-263586-index.html Edgar Link pending
0001193125-18-263586.txt Edgar Link pending
0001193125-18-263586-xbrl.zip Edgar Link pending
d533269d10k.htm Edgar Link pending
d533269dex231.htm Edgar Link pending
d533269dex311.htm Edgar Link pending
d533269dex312.htm Edgar Link pending
d533269dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g533269g05t48.jpg Edgar Link pending
g533269g55m78.jpg Edgar Link pending
g533269g75g26.jpg Edgar Link pending
meip-20180630.xml Edgar Link completed
meip-20180630.xsd Edgar Link pending
meip-20180630_cal.xml Edgar Link unprocessable
meip-20180630_def.xml Edgar Link unprocessable
meip-20180630_lab.xml Edgar Link unprocessable
meip-20180630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending